<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228445</url>
  </required_header>
  <id_info>
    <org_study_id>PVP-19IC01</org_study_id>
    <nct_id>NCT04228445</nct_id>
  </id_info>
  <brief_title>3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency</brief_title>
  <acronym>UP</acronym>
  <official_title>An Open-Label Study of Two Different Doses of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution When Used as an Aid for Ureteral Patency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prove pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prove pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the use of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium&#xD;
      0.8% Solution for injection provides a visualization advantage compared to saline when used&#xD;
      as an aid in the determination of ureteral patency&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, multicenter study to evaluate the efficacy, safety, and&#xD;
      pharmacokinetics of two doses (2.5 mL and 5.0 mL) of&#xD;
      3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium solution for injection when used as&#xD;
      an aid in the determination of ureteral patency. Study will enroll up to 116 subjects from&#xD;
      approximately 10 study centers in the United States.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Actual">June 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-point Ureteral Orifice Visualization Scale (UOVS) determination of ureteral patency.</measure>
    <time_frame>10 minutes</time_frame>
    <description>Visualization will be measured by a 3-point Ureteral Orifice Visualization&#xD;
Scale (UOVS):&#xD;
= non-visualization&#xD;
= inadequate/equivocal visualization&#xD;
= adequate/unequivocal visualization of the urine jet stream after administration of test age</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Ureter Injury</condition>
  <arm_group>
    <arm_group_label>HIGH DOSE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 subjects randomly treated with 5 mL of drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOW DOSE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 subjects randomly treated with 2.5 mL of drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>96 subjects treated with 5 ml of saline than crossover to treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%</intervention_name>
    <description>Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.</description>
    <arm_group_label>HIGH DOSE</arm_group_label>
    <arm_group_label>LOW DOSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline spray</intervention_name>
    <description>Placebo</description>
    <arm_group_label>HIGH DOSE</arm_group_label>
    <arm_group_label>LOW DOSE</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between ≥ 18 and ≤ 85 years old.&#xD;
&#xD;
          -  Subjects who signed written, IRB approved, informed consent form.&#xD;
&#xD;
          -  Subjects scheduled for urological or gynecological surgical procedures in which the&#xD;
             patency of the ureter must be assessed by the surgeon during the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with stage 4 or 5 Chronic Kidney Failure as evidenced by a GFR &lt;30&#xD;
             mL/min/1.73m2 (using the MDRD) or need for dialysis in the near future, or having only&#xD;
             1 kidney.&#xD;
&#xD;
          -  Subjects with known severe hypersensitivity reactions to IC or other dyes including&#xD;
             contrast agents.&#xD;
&#xD;
          -  Known history of drug or alcohol abuse within 6 months prior to the time of screening&#xD;
             visit.&#xD;
&#xD;
          -  Subjects, as assessed by the Investigator, with conditions/concomitant diseases&#xD;
             precluding their safe participation in this study (e.g. major systemic diseases).&#xD;
&#xD;
          -  Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is&#xD;
             uncooperative or has a condition that could lead to non-compliance with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist,&#xD;
             study coordinator, other staff or relative thereof directly involved in the conduct of&#xD;
             the protocol;&#xD;
&#xD;
          -  Subjects with life expectancy &lt; 6 months;&#xD;
&#xD;
          -  Requirement for concomitant treatment that could bias primary evaluation.&#xD;
&#xD;
          -  Subjects who are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Koch</last_name>
    <role>Study Director</role>
    <affiliation>Prove pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adult and Pediatric Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

